One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
The 2021 EULAR/American College of Rheumatology points to consider for diagnosis, management and monitoring of the interleukin-1 mediated autoinflammatory diseases: cryopyrin-associated periodic syndromes, tumour necrosis factor receptor-associated periodic syndrome, mevalonate kinase deficiency, and deficiency of the interleukin-1 receptor antagonist
Micol Romano, Z Serap Arici, David Piskin, Sara Alehashemi, Daniel Aletaha, Karyl S Barron, Susanne Benseler, Roberta Berard, Lori Broderick, Fatma Dedeoglu, Michelle Diebold, Karen L Durrant, Polly Ferguson, Dirk Foell, Jonathan Hausmann, Olcay Y Jones, Daniel L Kastner, Helen J Lachmann, Ronald M Laxer, Dorelia Rivera, Nicolino Ruperto, Anna Simon, Marinka Twilt, Joost Frenkel, Hal Hoffman, Adriana A de Jesus, Jasmin Beate Kuemmerle-Deschner, Seza Ozen, Marco Gattorno, Raphaela Goldbach-Mansky, Erkan Demirkaya
doi : 10.1136/annrheumdis-2021-221801
July 2022 - Volume 81 - 7
Eleonora Reicher: a pioneer of European rheumatology
Eugene J Kucharz
Low dose, add-on prednisolone in patients with rheumatoid arthritis aged 65+: the pragmatic randomised, double-blind placebo-controlled GLORIA trial
Maarten Boers, Linda Hartman, Daniela Opris-Belinski, Reinhard Bos, Marc R Kok, Jose AP Da Silva, Eduard N Griep, Ruth Klaasen, Cornelia F Allaart, Paul Baudoin, Hennie G Raterman, Zoltan Szekanecz, Frank Buttgereit, Pavol Masaryk, L Thomas Klausch, Sabrina Paolino, Annemarie M Schilder, Willem F Lems, Maurizio Cutolo
Systematic literature review of observational cohorts and clinical trials into the success rate of glucocorticoid discontinuation after their use as bridging therapy in patients with rheumatoid arthritis
Lotte van Ouwerkerk, Andriko Palmowski, Isabell S Nevins, Frank Buttgereit, Patrick Verschueren, Josef S Smolen, Robert BM Landewé, Johannes JW Bijlsma, Andreas Kerschbaumer, René Westhovens, Tom WJ Huizinga, Cornelia F Allaart, Sytske Anne Bergstra
Safety of ixekizumab in patients with psoriatic arthritis: data from four clinical trials with over 2000 patient-years of exposure
Atul A Deodhar, Bernard Combe, Ana P Accioly, Rebecca Bolce, Danting Zhu, Amanda M Gellett, Aubrey Trevelin Sprabery, Gerd-Rüdiger R Burmester
Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials
Edward M Vital, Joan T Merrill, Eric F Morand, Richard A Furie, Ian N Bruce, Yoshiya Tanaka, Susan Manzi, Kenneth C Kalunian, Rubana N Kalyani, Katie Streicher, Gabriel Abreu, Raj Tummala
Concordance and discordance in SLE clinical trial outcome measures: analysis of three anifrolumab phase 2/3 trials
Ian N Bruce, Richard A Furie, Eric F Morand, Susan Manzi, Yoshiya Tanaka, Kenneth C. Kalunian, Joan T Merrill, Patricia Puzio, Emmanuelle Maho, Christi Kleoudis, Marius Albulescu, Micki Hultquist, Raj Tummala
Characteristics associated with poor COVID-19 outcomes in individuals with systemic lupus erythematosus: data from the COVID-19 Global Rheumatology Alliance
Manuel Francisco Ugarte-Gil, Graciela S Alarcón, Zara Izadi, Ali Duarte-GarcÃa, Cristina Reátegui-Sokolova, Ann Elaine Clarke, Leanna Wise, Guillermo J Pons-Estel, Maria Jose Santos, Sasha Bernatsky, Sandra Lúcia Euzébio Ribeiro, Samar Al Emadi, Jeffrey A Sparks, Tiffany Y -T Hsu, Naomi J Patel, Emily L Gilbert, Maria O Valenzuela-Almada, Andreas Jönsen, Gianpiero Landolfi, Micaela Fredi, Tiphaine Goulenok, Mathilde Devaux, Xavier Mariette, Viviane Queyrel, Vasco C Romão, Graca Sequeira, Rebecca Hasseli, Bimba Hoyer, Reinhard E Voll, Christof Specker, Roberto Baez, Vanessa Castro-Coello, Hernan Maldonado Ficco, Edgard Torres Reis Neto, Gilda Aparecida Aparecida Ferreira, Odirlei Andre André Monticielo, Emily Sirotich, Jean Liew, Jonathan Hausmann, Paul Sufka, Rebecca Grainger, Suleman Bhana, Wendy Costello, Zachary S Wallace, Lindsay Jacobsohn, Tiffany Taylor, Clairissa Ja, Anja Strangfeld, Elsa F Mateus, Kimme L Hyrich, Loreto Carmona, Saskia Lawson-Tovey, Lianne Kearsley-Fleet, Martin Schäfer, Pedro M Machado, Philip C Robinson, Milena Gianfrancesco, Jinoos Yazdany
Development and preliminary validation of the Sjögren’s Tool for Assessing Response (STAR): a consensual composite score for assessing treatment effect in primary Sjögren’s syndrome
Raphaele Seror, Gabriel Baron, Marine Camus, Divi Cornec, Elodie Perrodeau, Simon J Bowman, Michele Bombardieri, Hendrika Bootsma, Jacques-Eric Gottenberg, Benjamin Fisher, Wolfgang Hueber, Joel A van Roon, Valérie Devauchelle-Pensec, Peter Gergely, Xavier Mariette, Raphael Porcher
Prevention of disease flares by risk-adapted stratification of therapy withdrawal in juvenile idiopathic arthritis: results from the PREVENT-JIA trial
Joachim Gerss, Monika Tedy, Ariane Klein, Gerd Horneff, Maria Miranda-Garcia, Christoph Kessel, Dirk Holzinger, Valda Stanevica, Joost F Swart, David A Cabral, Hermine I Brunner, Dirk Foell
Outcomes of SARS-CoV-2 infection among children and young people with pre-existing rheumatic and musculoskeletal diseases
Lianne Kearsley-Fleet, Min-Lee Chang, Saskia Lawson-Tovey, Ruth Costello, Šárka Fingerhutová, Natálie Švestková, Alexandre Belot, Florence A Aeschlimann, Isabelle Melki, Isabelle Koné-Paut, Sascha Eulert, Tilmann Kallinich, Yackov Berkun, Yosef Uziel, Bernd Raffeiner, Filipa Oliveira Ramos, Daniel Clemente, Christina Dackhammar, Nico M Wulffraat, Helen Waite, Anja Strangfeld, Elsa F Mateus, Pedro M Machado, CARRA Registry Investigators, COVID-19 Global Pediatric Rheumatology Database Investigators, Marc Natter, Kimme L Hyrich
Tfh cells with NLRP3 inflammasome activation are essential for high-affinity antibody generation, germinal centre formation and autoimmunity
Zhenhuan Zhao, Bihua Xu, Shuang Wang, Mianjing Zhou, Yuefang Huang, Chaohuan Guo, Mengyuan Li, Jijun Zhao, Sun-Sang J Sung, Felicia Gaskin, Niansheng Yang, Shu Man Fu
Better outcomes of COVID-19 in vaccinated compared to unvaccinated patients with systemic rheumatic diseases
Charalampos Papagoras, George E Fragoulis, Nikoleta Zioga, Theodora Simopoulou, Kleopatra Deftereou, Eleni Kalavri, Evangelia Zampeli, Nafsika Gerolymatou, Evangelia Kataxaki, Konstantinos Melissaropoulos, Stylianos Panopoulos, Kalliopi Fragiadaki, Gerasimos Evangelatos, Vasiliki-Kalliopi Bournia, Aikaterini Arida, Anastasios Karamanakos, Maria Pappa, Alexandros Panagiotopoulos, Christos Koutsianas, Georgia Mparouta, Theodoros Dimitroulas, Stamatis-Nick Liossis, Maria G Tektonidou, Evrydiki Kravvariti, Nikolaos Kougkas, Panagiotis Georgiou, Paraskevi Voulgari, Antonia Elezoglou, Dimitrios P Bogdanos, Dimitrios Vassilopoulos, Petros P Sfikakis
Response to SARS-CoV-2 vaccination in systemic autoimmune rheumatic disease depends on immunosuppressive regimen: a matched, prospective cohort study
Peter Mandl, Selma Tobudic, Helmut Haslacher, Thomas Karonitsch, Daniel Mrak, Thomas Nothnagl, Thomas Perkmann, Helga Radner, Judith Sautner, Elisabeth Simader, Florian Winkler, Heinz Burgmann, Daniel Aletaha, Stefan Winkler, Stephan Blüml
Efficacy and safety of SARS-CoV-2 revaccination in non-responders with immune-mediated inflammatory disease
David Simon, Koray Tascilar, Filippo Fagni, Katja Schmidt, Gerhard Krönke, Arnd Kleyer, Andreas Ramming, Verena Schoenau, Daniela Bohr, Johannes Knitza, Thomas Harrer, Karin Manger, Bernhard Manger, Georg Schett
BNT162b2 mRNA COVID-19 vaccine and booster in patients with autoimmune rheumatic diseases: a national cohort study
Amir Bieber, Iftach Sagy, Lena Novack, Shay Brikman, Ran Abuhasira, Snait Ayalon, Irina Novofastovski, Mahmoud Abu-Shakra, Reuven Mader
Increment of immunogenicity after third dose of a homologous inactivated SARS-CoV-2 vaccine in a large population of patients with autoimmune rheumatic diseases
Nádia Emi Aikawa, Leonard de Vinci Kanda Kupa, Ana Cristina Medeiros-Ribeiro, Carla Goncalves Schahin Saad, Emily Figueiredo Neves Yuki, Sandra Gofinet Pasoto, Priscila Tagliaferro Rojo, Rosa Maria Rodrigues Pereira, Samuel Katsuyuki Shinjo, Percival Degrava Sampaio-Barros, Danieli Castro Oliveira Andrade, Ari Stiel Radu Halpern, Ricardo Fuller, Fernando Henrique Carlos Souza, Lissiane Karine Noronha Guedes, Ana Paula Luppino Assad, Julio Cesar Bertacini de Moraes, Michelle Remiao Ugolini Lopes, Victor Adriano de Oliveira Martins, Lorena Betancourt, Carolina Torres Ribeiro, Lucas Peixoto Sales, Isabela Maria Bertoglio, Virginia Lucia Nazario Bonoldi, Renata Lys Pinheiro Mello, Gustavo Guimaraes Moreira Balbi, Ana Marli Christovam Sartori, Leila Antonangelo, Clóvis Artur Silva, Eloisa Bonfa
Neutralisation of circulating SARS-CoV-2 delta and omicron variants by convalescent plasma and SARS-CoV-2 hyperimmune intravenous human immunoglobulins for treatment of COVID-19
Fatema Tuz Zahra, Lorenza Bellusci, Gabrielle Grubbs, Hana Golding, Surender Khurana
Rheumatoid arthritis disease activity assessed by patient-reported outcomes and flow cytometry before and after an additional dose of COVID-19 vaccine
Sara K Tedeschi, Jacklyn Stratton, Jack Elias Ellrodt, Mary Grace Whelan, Keigo Hayashi, Kazuki Yoshida, Lin Chen, Ifeoluwakiisi Adejoorin, Kathryne Elizabeth Marks, A. Helena Jonsson, Deepak A Rao, Daniel H Solomon
Comparative analysis of SGLT-2 expression in renal vasculitis and lupus nephritis
Samy Hakroush, Desiree Tampe, Ingmar Alexander Kluge, Eva Baier, Peter Korsten, Björn Tampe
Pilot study of baricitinib for active Sjogren’s syndrome
Wei Bai, Huilan Liu, Lei Dou, YunJiao Yang, XiaoMei Leng, Mengtao Li, Wen Zhang, Yan Zhao, Xiaofeng Zeng
Management of rheumatoid arthritis in China: a study of the implementation of 2019 EULAR recommendations
Shangyi Jin, Nan Jiang, Yuehong Huo, Xinwang Duan, Yongfei Fang, Cheng Zhao, Hongbin Li, Min Yang, Zhirao Huang, Pingting Yang, Hongfeng Zhang, Feng Zhan, Youlian Wang, Yanhong Wang, Chanyuan Wu, Qian Wang, Evelyn Hsieh, Mengtao Li, Xinping Tian, Yan Zhao, Xiaofeng Zeng
High risk of systemic lupus erythematosus development in patients with ITP: antiphospholipid syndrome is also a concern
Murat İnanç, Bahar Artim-Esen, Reyhan Diz-Küçükkaya
Response to: ‘High risk of systemic lupus erythematosus development in patients with ITP: antiphospholipid syndrome is also a concern?’ by Inanc et al
James Cheng-Chung Wei, Fang Xiao Zhu, Jing-Yang Huang
Risk of systemic lupus erythematosus in patients with idiopathic thrombocytopenic purpura: population-based cohort study
George N Goulielmos, Maria I Zervou
Response to: ‘Risk of systemic lupus erythematosus in patients with idiopathic thrombocytopenic purpura: population-based cohort study’ by Goulielmos and Zervou
Fang Xiao Zhu, Jing-Yang Huang, James Cheng-Chung Wei
Microbiome in Sjögren’s syndrome: here we are
Taco A van der Meulen, Arjan Vissink, Hendrika Bootsma, Fred K L Spijkervet, Frans G M Kroese
Response to: ‘Microbiome in Sjögren’s syndrome: here we are’ by van der Meulen et al
Julia Manasson, Rebecca B Blank, Jose U Scher
Riociguat in systemic sclerosis: a potential for disease modification
Siddharth Jain, Varun Dhir
Response to: ‘Riociguat in systemic sclerosis: a potential for disease modification’ by Jain and Dhir
Dinesh Khanna, Oliver Distler
‘Halo Score’: missing large-vessel giant cell arteritis— do we need a ‘modified Halo Score’?
Arghya Chattopadhyay, Alakendu Ghosh
Response to: ‘‘Halo Score’: missing large vessel giant cell arteritis– do we need a modified ‘Halo Score?’’ by Chattopadhyay and Ghosh
Kornelis S M van der Geest, Bhaskar Dasgupta
Eosinophilic granulomatosis with polyangiitis can manifest lacrimal and salivary glands swelling by granulomatous inflammation: a potential mimicker of IgG4-related disease
Mitsuhiro Akiyama, Yuko Kaneko, Tsutomu Takeuchi
Response to: ‘Eosinophilic granulomatosis with polyangiitis can manifest lacrimal and salivary glands swelling by granulomatous inflammation: a potential mimicker of IgG4-related disease’ by Akiyama et al
Augusto Vaglio, Federica Maritati, Jochen Zwerina
Confounding by indication and ethnicity difference? Comment on ‘Hypersensitivity reactions with allopurinol and febuxostat: a study using the Medicare claims data’
Po-Ke Hsu, Yung-Heng Lee, James Cheng Chung Wei
Response to: ‘Confunding by indication and ethnicity difference? Comment on ‘Hypersensitivity reactions with allopurinol and febuxostat: a study using the Medicare claims data’’ by Hsu et al
Jasvinder A Singh1,2
Cutaneous adverse events with febuxostat after previous reactions to allopurinol: comment on the article by Singh and Cleveland
Neus Quilis, Paloma Vela, Boris A Blanco Cáceres, Cesar Diaz-Torne, Enrique Calvo-Aranda, Francisca Sivera, Alejandro Prada-Ojeda, Fernando Pérez Ruiz, Eliseo Pascual, Mariano Andrés
Response to: ‘Cutaneous adverse events with febuxostat after previous reactions to allopurinol: comment on the artcile by Singh and Clevland’ by Quills et al
Jasvinder A Singh1,2
Changes in synovitis and bone marrow lesions may not mediate the effect of cartilage loss on joint pain in osteoarthritis
Aidan G Cashin, James H McAuley, Hopin Lee
Relation between cartilage loss and pain in knee osteoarthritis
Xiang-Dong Wu, Di Wu, Wei Huang, Gui-Xing Qiu
Response to: ‘Relation between cartilage loss and pain in knee osteoarthritis’ by Wu et al and ‘Changes in synovitis and bone marrow lesions may not mediate the effect of cartilage loss on joint pain in osteoarthritis’ by Cashin et al
Kathryn Bacon, Michael P LaValley, S Reza Jafarzadeh, David Felson
Beware of wolves in sheep's clothing: immune cell plasticity and instability in health and disease
Alessia Alunno, Onelia Bistoni, Roberto Gerli
Response to: ‘Beware of wolves in sheep's clothing: immune cell plasticity and instability in health and disease’ by Alunno et al
Abdulla Watad, Hannah Rowe, Darren Newton, Charlie Bridgewood, Dennis G McGonagle
Incidence of severe COVID-19 in a Spanish cohort of 1037 patients with rheumatic diseases treated with biologics and JAK-inhibitors
Vega Jovani, Irene Calabuig, Maria Luisa Peral-Garrido, Ernesto Tovar-Sugrañes, MarÃa-del-Carmen López-González, Pilar Bernabeu, AgustÃn MartÃnez, Joaquim Esteve-Vives, Jose-Manuel León-RamÃrez, Oscar Moreno-Perez, Vicente Boix, Joan Gil, Esperanza Merino, Paloma Vela, Mariano Andrés
Response to: ‘Incidence of severe COVID-19 in a Spanish cohort of 1037 patients with rheumatic diseases treated with biologics and JAK-inhibitors’ by Jovani et al
Kristin M D’Silva, Naomi Serling-Boyd, Rachel Wallwork, Tiffany Hsu, Jeffrey A Sparks, Zachary S Wallace
Correction: Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study
